Pharmaceutical

Health Canada approves Telix’s Illuccix label expansion

Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in PSMA targeted radionuclide therapy.

Oct 8, 2024 - 04:00
Health Canada approves Telix’s Illuccix label expansion
Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in PSMA targeted radionuclide therapy.
Read the original article

Tags:

Previous Article

ProductLife boosts drug development with IntiQuan acquisition

Next Article

OnKure and Reneo Pharmaceuticals complete merger

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pharmaceutical packaging companies and labelling machines

Mar 26, 2024

EU CHMP snubs Biogen and Eisai’s Alzheimer’s therapy Leqembi

EU CHMP snubs Biogen and Eisai’s Alzheimer’s therapy Le...

Jul 30, 2024

STAT+: Teladoc stock slides despite business growth, Medtronic CEO talks innovation

STAT+: Teladoc stock slides despite business growth, Me...

Oct 26, 2023